Abstract：【Objective】This study aimed to investigate the impact of carituzumab monoclonal antibody combined with chemotherapy on the three-year survival time in elderly patients with lung cancer. 【Methods】Eighty elderly patients with lung cancer admitted to our hospital were randomly divided into two groups, with 40 patients in each group. The control group received conventional chemotherapy, while the observation group received carituzumab monoclonal antibody treatment on the basis of chemotherapy. The clinical efficacy, serum T lymphocyte subsets levels before and after treatment, Karnofsky performance status (KPS) score, adverse event incidence, and three-year survival were compared between the two groups. 【Results】The objective response rate in the observation group was 55.00% (22/40), which was significantly higher than that in the control group 32.50% (13/40) (P<0.05). There was no significant difference in disease control rate between the two groups (P>0.05). After treatment, the levels of CD4+ and CD4+/CD8+ in both groups increased, while CD8+ decreased compared to before treatment (P<0.05). after treatment, the levels of CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group, while CD8+ of the observation group was lower that of the control group (P<0.05). The KPS scores of both groups after treatment was higher than those before treatment (P<0.05); And the observation group had a higher KPS score than the control group (P<0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P>0.05). During the 3-year follow-up period, 8 patients were lost to follow-up in the observation group, while there were 23 deaths and 9 survivors. Meanwhile, in the control group, 6 patients were lost to follow-up; And there were 28 deaths and 6 survivors. Kaplan-Meier survival analysis showed no significant difference in survival rates between the two groups (P>0.05). 【Conclusion】Carituzumab monoclonal antibody combined with chemotherapy has better efficacy in the treatment of elderly patients with lung cancer, which improves patient immune function. And it is safe and reliable.
郭宏果, 刘军, 程才, 乔松, 陆婉玲. 卡瑞利珠单抗联合化疗对老年肺癌患者的疗效及生存情况的影响[J]. 医学临床研究, 2023, 40(7): 1039-1042.
GUO Hong-guo, LIU Jun, CHENG Cai, et al. Effect of Carituzumab Monoclonal Antibody Combined with Chemotherapy on Efficacy and Survival in Elderly Patients with Lung Cancer. JOURNAL OF CLINICAL RESEARCH, 2023, 40(7): 1039-1042.
[1] ALLARDINI P, INCASA E, NOCE A D, et al. Spontaneous splenic rupture after the start of lung cancer chemotherapy. a case report[J].Tumori,2004, 90(1):144-146.
[2] BUSTAMANTE A J G, GONZÁLEZ-CAO M. Advances in immunotherapy for treatment of lung cancer[J].Cancer Biol Med, 2015,12(3):209-222.
[3] 赵秋玲,杨琳,谢瑞祥.9种获批上市的抗PD-1/PD-L1单抗药物的特征综述[J].中国药房,2020,31(18):2294-2299.
[4] 罗详冲,李高峰.PD-1抑制剂卡瑞利珠单抗在晚期恶性肿瘤中的应用进展[J].解放军医学杂志,2020,45(6):672-679.
[5] 李东航,姚颐,耿庆. 中国临床肿瘤学会肺癌诊疗指南(2018版)更新解读[J].临床外科杂志,2019,27(1):36-39.
[6] EISENHAUER E A, THERASSE P, BOGAERTS J, et al.New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1).[J].Eur J Cancer,2009, 45(2):228-247.
[7] WANG Y L,CHEN T T,DU J, Application of karnofsky performance scale in nursing of tumor patients receiving radiotherapy[J].PLA J Nursing,2007,24(10):14-15.
[8] ALDAROUISH M, WANG C . Trends and advances in tumor immunology and lung cancer immunotherapy[J].J Exp Clin Cancer Res,2016, 35(1):157.
[9] 燕翔,赵晓,焦顺昌,等. 晚期肺腺癌患者一线化疗后T淋巴细胞亚群变化及临床意义[J].中国肺癌杂志,2012,15(3):164-171.
[10] 邹春英,吕培中,宗峰,等. 老年肺癌患者血清T淋巴细胞亚群CD28的检测及临床意义[J].中华肿瘤防治杂志,2007,14(18):1389-1391.
[11] 涂建仁,付华珍.卡瑞利珠单抗联合化疗一线治疗晚期/转移性非鳞状非小细胞肺癌疗效观察[J].药品评价,2020,17(19):38-40.
[12] ZITVOGEL L, KROEMER G . Targeting PD-1/PD-L1 interactions for cancer immunotherapy[J].Oncoimmunology,2012, 1(8):1223-1225.
[13] 吴克林,吴天英,许海.卡瑞利珠单抗联合化疗对老年非小细胞肺癌患者血清细胞角蛋白19片段抗原21-1、基质金属蛋白酶9表达及肿瘤生长转移的影响[J].实用医学杂志,2020,36(20):2830-2833.
2023, Vol. 40 
